期刊文献+
共找到38篇文章
< 1 2 >
每页显示 20 50 100
Diagnostic Value of the Padua Score Combined with Thrombotic Biomarker Tissue Plasminogen Activator Inhibitor-1 (tPAI-1) Detection for the Risk of Deep Vein Thrombosis in Patients with Pulmonary Heart Disease
1
作者 Xiaoyun Zhang Xinlong Xi +1 位作者 Wenming Bian Qiang Liu 《Journal of Clinical and Nursing Research》 2024年第8期137-144,共8页
This study explores the diagnostic value of combining the Padua score with the thrombotic biomarker tissue plasminogen activator inhibitor-1(tPAI-1)for assessing the risk of deep vein thrombosis(DVT)in patients with p... This study explores the diagnostic value of combining the Padua score with the thrombotic biomarker tissue plasminogen activator inhibitor-1(tPAI-1)for assessing the risk of deep vein thrombosis(DVT)in patients with pulmonary heart disease.These patients often exhibit symptoms similar to venous thrombosis,such as dyspnea and bilateral lower limb swelling,complicating differential diagnosis.The Padua Prediction Score assesses the risk of venous thromboembolism(VTE)in hospitalized patients,while tPAI-1,a key fibrinolytic system inhibitor,indicates a hypercoagulable state.Clinical data from hospitalized patients with cor pulmonale were retrospectively analyzed.ROC curves compared the diagnostic value of the Padua score,tPAI-1 levels,and their combined model for predicting DVT risk.Results showed that tPAI-1 levels were significantly higher in DVT patients compared to non-DVT patients.The Padua score demonstrated a sensitivity of 82.61%and a specificity of 55.26%at a cutoff value of 3.The combined model had a significantly higher AUC than the Padua score alone,indicating better discriminatory ability in diagnosing DVT risk.The combination of the Padua score and tPAI-1 detection significantly improves the accuracy of diagnosing DVT risk in patients with pulmonary heart disease,reducing missed and incorrect diagnoses.This study provides a comprehensive assessment tool for clinicians,enhancing the diagnosis and treatment of patients with cor pulmonale complicated by DVT.Future research should validate these findings in larger samples and explore additional thrombotic biomarkers to optimize the predictive model. 展开更多
关键词 Padua prediction score Tissue plasminogen activator inhibitor-1(tPAI-1)detection Deep vein thrombosis(DVT) Pulmonary heart disease(cor pulmonale) Diagnostic accuracy
下载PDF
Association of plasminogen activator inhibitor-1 4G/5G promoter polymorphism with recurrent cerebral infarction in China’s North Jiangsu Province 被引量:1
2
作者 Deqin Geng Jijun Zhu +4 位作者 Guofang Chen Xianbi Tang Qiaoyun Yang Jizhen Li Fumin Liu 《Neural Regeneration Research》 SCIE CAS CSCD 2008年第7期791-794,共4页
BACKGROUND: Many international studies have shown that plasminogen activator inhibitor-1 (PAl-l) 4G/5G promoter polymorphism does not increase the risk for cerebral infarction. OBJECTIVE: Using PCR methodology and... BACKGROUND: Many international studies have shown that plasminogen activator inhibitor-1 (PAl-l) 4G/5G promoter polymorphism does not increase the risk for cerebral infarction. OBJECTIVE: Using PCR methodology and agarose electrophoresis to detect PAI-1 4G/5G promoter polymorphism in patients with recurrent cerebral infarction in the North Jiangsu Province of China, and to compare results with healthy subjects and patients with first-occurrence cerebral infarction in the same region. DESIGN, TIME AND SETTING: Non-randomized, concurrent, control trial. A total of 122 cerebral infarction patients were admitted to Xuzhou Medical College Hospital's Department of Neurology and Xuzhou Central Hospital's Department of Neurology between July 2003 and August 2006. PARTICIPANTS: The patients consisted of 63 males and 59 females, aged (62 ± 10) years. They were divided into first-occurrence (n = 58) and recurrence (n = 64) groups. In addition, 50 healthy subjects that underwent physical examination in the outpatient department, including 26 males and 24 females, aged (60 ±12) years, were selected as controls. METHODS AND MAIN OUTCOME MEASURES: PAl-1 4G/5G promoter polymorphism was detected and analyzed using PCR methodology and agarose electrophoresis. RESULTS: Significant differences were determined in terms of genotypic frequency and allele frequency of PAI-1 4G/5G promoter polymorphism, in patients with first-occurrence or recurrent cerebral infarction, when compared with healthy subjects (P 〈 0.05). There was, however, no significant difference between the first-occurrence and recurrence groups (P 〉 0.05). CONCLUSION: PAl- 1 4G/5G promoter polymorphism is genetic risk factor for cerebral infarction in China. However, it may be associated with recurrence of cerebral infarction in patients from the North Jiangsu Province of China. 展开更多
关键词 plasminogen activator inhibitor- 1 GENE POLYMORPHISM recurrent cerebral infarction
下载PDF
Study on Effect of Different Dosages of Ligustrazine on Level of Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes Mellitus Patients
3
作者 薛现中 张兆华 邢小燕 《Chinese Journal of Integrated Traditional and Western Medicine》 2003年第3期199-203,共5页
Objective: To observe the effect of different dosages of ligustrazine (LG) on the level of plasminogen activator inhibitor-1 (PAI-1) activity in patients with type 2 diabetes mellitus. Methods: Ninety cases of type 2 ... Objective: To observe the effect of different dosages of ligustrazine (LG) on the level of plasminogen activator inhibitor-1 (PAI-1) activity in patients with type 2 diabetes mellitus. Methods: Ninety cases of type 2 diabetes mellitus inpatients were selected, and randomly divided into LG small dosage group (SDG), LG large dosage group (LDG) and control group. The 120 mg LG, 400 mg LG and normal saline 250 ml were given through intravenous dripping respectively, once daily, 20 days as one treatment course. Before and after treatment, all the patients had their fasting blood taken for PAI-1 and tissue plasminogen activator (t-PA) assessment test to perform the comparative study. Results:Seventy-three out of the 90 patients completed the observation course, the PAI-1 activity of three groups after treatment all lowered compared with that before treatment, and the difference between groups was also significant (all P<0. 01). After treatment the PAI-1 level of SDG and LDG of LG were all markedly lowered (all P<0. 01), the LDG's lowering was more evident than that of SDG, and comparison between these two groups of patients showed significant difference (P<0. 01). Although in the control group there was some difference between before and after treatment, it was not so significant like the above-mentioned two groups (P = 0. 0140). No adverse reaction occurred in the 3 groups during the observation period. Conclusion:LG could safely and effectively lower type 2 diabetes mellitus patient's plasma PAI-1 activity level, and LDG of LG proved to be particularly effective. 展开更多
关键词 type 2 diabetes mellitus LIGUSTRAZINE plasminogen activator inhibitor-1
下载PDF
Research on the correlation of serum plasminogen activator inhibitor-1 level to vascular complications in type 2 diabetes mellitus patients with overweight or obesity
4
作者 Jun X Yanan Z +5 位作者 Zhijie C Zhihui D Danhua S Xiaojing C Ying W Jixiang J 《Discussion of Clinical Cases》 2019年第2期20-25,共6页
Objective:To explore the relationship between serum plasminogen activator inhibitor(PAI-1)level and Type 2 Diabetes Mellitus(T2DM)accompanied by overweight or obesity by observing not only the changes of PAI-1 level i... Objective:To explore the relationship between serum plasminogen activator inhibitor(PAI-1)level and Type 2 Diabetes Mellitus(T2DM)accompanied by overweight or obesity by observing not only the changes of PAI-1 level in T2DM patients with overweight or obesity,but also glucose and lipid metabolism related indicators,the changes of the inflammatory cytokines secreted by adipocytes,and then making an analysis on the correlation to PAI-1.Methods:36 cases of healthy examinees were selected as normal control group(NC group),and the experimental group can be divided into T2DM group(54 cases),Overweight/Obesity group(35 cases)and T2DM+Overweight/Obesity group(48 cases).Glucose and lipid metabolism related indicators such as fasting blood glucose(FBG),triglyceride(TG),total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),glycated hemoglobin(HbA1c),fasting insulin(FINS),insulin resistance index(IR),body weight index(BMI)and inflammatory cytokines interleukin-6(IL-6),tumor necrosis factor(TNF-α)and PAI-1 were observed and compared between groups,and then made an analysis to explore the correlation of these factors to PAI-1.Results:(1)Compared with NC group,the levels of FBG,HbA1c,FINS and IR were increased in T2DM group,and the difference was of statistical significance.However,there was no statistically significant difference in TG,TC,LDL-C and BMI between NC group and T2DM group;the levels of FINS,IR,TG,LDL-C,TC and BMI were elevated in Overweight/Obesity group,and the difference was of statistical significance.However,there was no statistically significant difference in FBG and HbA1c;the levels of FBG,HbA1c,FINS,IR,TG,LDL-C,TC and BMI were up-regulated in T2DM+Overweight/Obesity group,and the difference was of statistical significance.Compared with T2DM group,the levels of TG,TC,LDL-C and BMI were increased in Overweight/Obesity group,and the difference was of statistical significance,however,the levels of FBG,HbA1c,FINS and IR were decreased,and the difference was statistically significant;The levels of FINS,IR,TG,TC,LDL-C and BMI were elevated in T2DM+Overweight/Obesity group,and the difference was of statistical significance,however,there was no statistically significant difference in FBG and HbA1c.Compared with Overweight/Obesity group,the levels of FBG,FINS,IR,HbA1c and LDL-C were increased in T2DM+Overweight/Obesity group,and the difference was of statistical significance.However,the difference in TG,TC and BMI was not statistically significant.(2)Compared with NC group,the levels of IL-6,TNF-αand PAI-1 were increased in T2DM group,Overweight/Obesity group and T2DM+Overweight/Obesity group,and the difference was statistically significant.Compared with T2DM group,the levels of IL-6 and TNF-αwere elevated in Overweight/Obesity group,and the difference was of statistical significance,but there was no statistically significant difference in PAI-1;the levels of IL-6,TNF-αand PAI-1 were up-regulated in T2DM+Overweight/Obesity group,and the difference was statistically significant.Compared with Overweight/Obesity group,there was no statistically significant difference in IL-6 and TNF-αbetween T2DM+Overweight/Obesity group and Overweight/Obesity group,but the level of PAI-1 was increased in T2DM+Overweight/Obesity group,and the difference was of statistical significance.(3)Multivariate Logistic Regression Analysis showed that HbA1c,IR,TG,BMI,IL-6 and TNF-αwere independently associated with the level of PAI-1(all p<.05).Conclusions:(1)The level of PAI-1 is higher in type 2 diabetes mellitus patients with overweight or obesity than that in patients only with type 2 diabetes mellitus,and it is one of causes that result in vascular complications.(2)The increase in the level of PAI-1 is considered to be associated with IL-6 and TNF-αsecreted by adipocytes. 展开更多
关键词 plasminogen activator inhibitor-1 Type 2 diabetes mellitus OVERWEIGHT/OBESITY
下载PDF
厄贝沙坦和依那普利对可溶性细胞间黏附分子-1和纤溶酶原激活物抑制剂-1表达的影响 被引量:2
5
作者 王大志 马新华 张书瑜 《中国医院药学杂志》 CAS CSCD 北大核心 2008年第17期1466-1468,共3页
目的:研究自发性高血压♂大鼠(SHR)与WKY大鼠间的血压、可溶性细胞间黏附分子(sICAM-1)和纤溶酶原激活物抑制剂-1(PAI-1)表达的变化以及厄贝沙坦(irbesartan)和依那普利(enalapril)对SHR大鼠对上述指标的影响。方法:将30只♂SHR随机分为... 目的:研究自发性高血压♂大鼠(SHR)与WKY大鼠间的血压、可溶性细胞间黏附分子(sICAM-1)和纤溶酶原激活物抑制剂-1(PAI-1)表达的变化以及厄贝沙坦(irbesartan)和依那普利(enalapril)对SHR大鼠对上述指标的影响。方法:将30只♂SHR随机分为3组,每组10只。一组为SHR-I组,每日灌喂厄贝沙坦30mg.kg-1。一组为SHR-E组,每日灌喂依那普利10mg.kg-1。另一组为SHR空白对照组,不给予药物,正常饮水。另取10只WKY为正常对照组与上述3组比较。以上各组都喂养14周。用酶联免疫吸附法(ELISA)和发色底物显色法分别对4组大鼠血浆sICAM-1和PAI-1的表达进行检测。结果:SHR大鼠的血压、sICAM-1和PAI-1的表达明显高于WKY大鼠。厄贝沙坦组和依那普利组的血压、sICAM-1和PAI-1都明显低于SHR空白对照组,但两治疗组间差异无显性。结论:SHR♂大鼠的血压、sICAM-1、PAI-1表达都显著高于WKY大鼠,厄贝沙坦和依那普利都能明显地降低SHR大鼠的血压、sICAM-1、PAI-1表达。 展开更多
关键词 自发性高血压大鼠 可溶性细胞间黏附分子-1 纤溶酶原激活物抑制剂-1 厄贝沙坦 依那普利
下载PDF
妊娠期糖尿病PAI-1 4G/5G基因多态性与胰岛素抵抗的相关性 被引量:2
6
作者 韩姹 牛秀敏 张慧英 《现代妇产科进展》 CSCD 北大核心 2008年第12期913-915,919,共4页
目的:探讨纤溶酶原激活物抑制剂-1(PAI-1)4G/5G基因多态性与天津及河北地区汉族人群中妊娠期糖尿病(GDM)发病及胰岛素抵抗(IR)的相关性。方法:用PCR方法检测GDM组和正常妊娠对照组(每组75例)PAI-1 4G/5G基因型,并分析相关临床资料。结果... 目的:探讨纤溶酶原激活物抑制剂-1(PAI-1)4G/5G基因多态性与天津及河北地区汉族人群中妊娠期糖尿病(GDM)发病及胰岛素抵抗(IR)的相关性。方法:用PCR方法检测GDM组和正常妊娠对照组(每组75例)PAI-1 4G/5G基因型,并分析相关临床资料。结果:GDM组4G/4G基因型频率及4G等位基因频率均高于正常对照组(P<0.05)。GDM组4G/4G基因型孕妇空腹胰岛素、胰岛素抵抗指数均高于5G/5G组(P<0.05)。结论:PAI-1 4G/5G基因多态性与GDM发病相关,4G/4G基因型可能是GDM的易感基因;PAI-1 4G/4G基因型与GDM患者IR的发生有关。 展开更多
关键词 糖尿病 妊娠 胰岛素抵抗 纤溶酶原激活物抑制剂1 基因多态性
下载PDF
uPA和PAI-1在人脑胶质瘤的表达及其与肿瘤血管生成的关系 被引量:2
7
作者 张文敏 黄纲雄 +3 位作者 黄爱民 高凌云 高美钦 陈碧芬 《解剖学研究》 CAS 2005年第1期15-18,共4页
目的探讨uPA、PAI鄄1和VEGF与人脑胶质瘤病理分级和侵袭行为的关系及各因子间的相互联系。方法采用免疫组化SP方法检测42例人脑胶质瘤和8例正常脑组织uPA、PAI鄄1和VEGF蛋白的表达。结果12例中低度恶性胶质瘤中,uPA、PAI鄄1和VEGF阳性... 目的探讨uPA、PAI鄄1和VEGF与人脑胶质瘤病理分级和侵袭行为的关系及各因子间的相互联系。方法采用免疫组化SP方法检测42例人脑胶质瘤和8例正常脑组织uPA、PAI鄄1和VEGF蛋白的表达。结果12例中低度恶性胶质瘤中,uPA、PAI鄄1和VEGF阳性表达率分别为58.3%、50.0%、33.3%,30例高度恶性胶质瘤的阳性率分别为96.7%、86.7%、93.3%,两组间各指标相比较,uPA和VEGF差异有极显著性(P<0.01),PAl鄄1差异有显著性(P<0.05)。uPA、PAI鄄1和VEGF阳性染色主要定位于血管内皮细胞和瘤细胞胞浆,以肿瘤侵袭边缘和坏死组织周围多见。uPA与VEGF、PAI鄄1与VEGF之间均呈明显正相关(P<0.05)。8例正常脑组织除1例有PAl鄄1微弱表达外,其余均为阴性。结论随脑胶质瘤恶性度增高,uPA、PAl鄄1和VEGF表达增强,三者协同作用,可作为胶质瘤恶性度高和侵袭能力强潜在的分子生物学指标。 展开更多
关键词 PAI-1 UPA VEGF 人脑胶质瘤 表达 正常 恶性 结论 相互联系 显著性
下载PDF
氯沙坦对自发性高血压大鼠主动脉内膜ICAM-1和PAI-1表达的影响 被引量:1
8
作者 黄俊 刘昌慧 张黎军 《微循环学杂志》 2004年第2期30-31,34,F004,共4页
目的 :比较早期雄性自发性高血压大鼠 (SHR)和正常雄性同周龄WistarKyoto大鼠 (WKY)主动脉内膜细胞间粘附分子 1(ICAM 1)和纤溶酶原激活物抑制剂 1(PAI 1)的表达及氯沙坦对其的影响。方法 :将 2 0只雄性SHR随机分成二组 ,每组 10只 ,... 目的 :比较早期雄性自发性高血压大鼠 (SHR)和正常雄性同周龄WistarKyoto大鼠 (WKY)主动脉内膜细胞间粘附分子 1(ICAM 1)和纤溶酶原激活物抑制剂 1(PAI 1)的表达及氯沙坦对其的影响。方法 :将 2 0只雄性SHR随机分成二组 ,每组 10只 ,其中一组灌喂氯沙坦 2 0mg/kg/天 ,另一对照组给正常饮水 ,共 12周 ,并与WKY 10只比较。采用免疫组织化学方法检测三组大鼠主动脉内膜ICAM 1和PAI 1的表达。结果 :与WKY大鼠比较 ,SHR对照组主动脉内膜ICAM 1和PAI 1表达明显增高 ;经氯沙坦治疗 12周后SHR血压显著降低 ,主动脉内膜ICAM 1和PAI 1表达亦明显下降。结论 :氯沙坦在有效降压的同时也明显抑制SHR主动脉内膜ICAM 1和PAI 1的表达 ,提示氯沙坦作为血管紧张素II受体 1拮抗剂 (AT1 R) 展开更多
关键词 氯沙坦 自发性高血压 大鼠 主动脉内膜 ICAM-1 PAI-1 并发症 免疫组织
下载PDF
淋巴瘤患者血液t-PA与PAI-1的变化及其意义 被引量:1
9
作者 李劲峰 《山西职工医学院学报》 CAS 2005年第1期10-13,共4页
目的 :研究非霍奇金氏淋巴瘤 (non Hodgkin’slymphoma ,NHL)血浆组织型纤溶酶原激活剂 (t PA)、纤溶酶原激活剂抑制剂 1(PAI 1)的水平与NHL各生理病理参数的关系。方法 :采用ELISA法检测 36例NHL患者血浆t PA、PAI 1的水平。结果 :NH... 目的 :研究非霍奇金氏淋巴瘤 (non Hodgkin’slymphoma ,NHL)血浆组织型纤溶酶原激活剂 (t PA)、纤溶酶原激活剂抑制剂 1(PAI 1)的水平与NHL各生理病理参数的关系。方法 :采用ELISA法检测 36例NHL患者血浆t PA、PAI 1的水平。结果 :NHL患者血浆t PA (18.6 9± 15.5 0 )ng/mL及PAI 1(74 .6 1± 19.2 7)ng/mL较对照组显著升高 (P均 <0 0 1)。Ⅰ期、Ⅱ期NHL患者血浆t PA (2 7.37± 2 0.0 7)ng/mL高于Ⅲ期、Ⅳ期 (15.0 3±8.80 )ng/mL(P <0.0 5 )。LDH异常的NHL患者PAI 1(77 0 3± 2 5 4 1)ng/mL高于LDH正常的NHL患者(44 .4 0± 19. 0 3)ng/mL(P <0.0 1)。结论 :NHL患者体内t PA、PAI-1的过度表达 ,血浆高t PA水平提示病变处于早期及预后较好。PAI-1血浆水平较高提示预后不良 。 展开更多
关键词 非霍奇金氏淋巴瘤 组织型纤溶酶原激活剂 纤溶酶原激活剂抑制剂-1
下载PDF
TNF-α对人脐静脉内皮细胞t-PA、PAI-1表达的研究
10
作者 陈懿建 郑永亮 +3 位作者 万通 张立群 辛柳燕 钟思思 《赣南医学院学报》 2014年第6期835-838,共4页
目的:观察肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)对人脐静脉内皮细胞(HUVECs)组织型纤溶酶原激活物(tissue plasminogen activitor,t-PA)及其抑制剂-1(plasminogen activitor inhibitor-1,PAI-1)表达的影响。方法:原代分离H... 目的:观察肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)对人脐静脉内皮细胞(HUVECs)组织型纤溶酶原激活物(tissue plasminogen activitor,t-PA)及其抑制剂-1(plasminogen activitor inhibitor-1,PAI-1)表达的影响。方法:原代分离HUVECs细胞并进行传代培养,分别以6个TNF-α浓度组(0、1、10、20、50、100 ng·m L-1)处理不同时间(0、1、3、6、12、24 h),酶联免疫吸附分析(ELISA)法测定t-PA、PAI-1抗原的表达;逆转-聚合酶链反应(RTPCR)检测t-PA、PAI-1基因的表达。结果:TNF-α促进PAI-1抗原的表达,并呈剂量和时间依赖关系,在TNF-α10 ng·m L-1作用6 h时最明显(P<0.01);TNF-α促进PAI-1 mRNA的表达,并呈剂量和时间依赖关系,在TNF-α10 ng·m L-1作用3 h时已非常明显(P<0.01),6 h时达到高峰(P<0.01);而TNF-α对HUVECs表达t-PA抗原、mRNA无明显影响。结论:炎症因子TNF-α可能通过上调PAI-1表达而诱发血栓相关疾病。 展开更多
关键词 肿瘤坏死因子-α 人脐静脉内皮细胞 纤溶酶原激活物 纤溶酶原激活物抑制物 tumor NECROSIS factor-α plasminogen ac-tivitor inhibitor-1
下载PDF
Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma 被引量:12
11
作者 Yan Zhang Ya-Lou Zhang +5 位作者 Hong-Ming Chen Hong-Wei Pu Wen-Jing Ma Xiao-Mei Li Hong Ma Xiao Chen 《World Journal of Gastroenterology》 SCIE CAS 2014年第18期5533-5539,共7页
AIM: To determine the correlation between invasiveness, migration and prognosis in esophageal squamous cell carcinoma (ESCC) and expression of the B-cell-specific Moloney leukemia virus insert site 1 (Bmi-1) and plasm... AIM: To determine the correlation between invasiveness, migration and prognosis in esophageal squamous cell carcinoma (ESCC) and expression of the B-cell-specific Moloney leukemia virus insert site 1 (Bmi-1) and plasminogen activator inhibitor-1 (PAI-1). 展开更多
关键词 Esophageal squamous cell carcinoma B-cell-specific moloney leukemia virus insert site 1 plasminogen activator inhibitor-1 METASTASIS Prognosis
下载PDF
The plasminogen activating system in the pathogenesis of Alzheimer’s disease 被引量:3
12
作者 Manuel Yepes 《Neural Regeneration Research》 SCIE CAS CSCD 2021年第10期1973-1977,共5页
Dementia is a clinical syndrome that affects approximately 47 million people worldwide and is characterized by progressive and irreversible decline of cognitive,behavioral and sesorimotor functions.Alzheimer’s diseas... Dementia is a clinical syndrome that affects approximately 47 million people worldwide and is characterized by progressive and irreversible decline of cognitive,behavioral and sesorimotor functions.Alzheimer’s disease(AD)accounts for approximately 60–80%of all cases of dementia,and neuropathologically is characterized by extracellular deposits of insoluble amyloid-β(Aβ)and intracellular aggregates of hyperphosphorylated tau.Significantly,although for a long time it was believed that the extracellular accumulation of Aβwas the culprit of the symptoms observed in these patients,more recent studies have shown that cognitive decline in people suffering this disease is associated with soluble Aβ-induced synaptic dysfunction instead of the formation of insoluble Aβ-containing extracellular plaques.These observations are translationally relevant because soluble Aβ-induced synaptic dysfunction is an early event in AD that precedes neuronal death,and thus is amenable to therapeutic interventions to prevent cognitive decline before the progression to irreversible brain damage.The plasminogen activating(PA)system is an enzymatic cascade that triggers the degradation of fibrin by catalyzing the conversion of plasminogen into plasmin via two serine proteinases:tissue-type plasminogen activator(tPA)and urokinase-type plasminogen activator(uPA).Experimental evidence reported over the last three decades has shown that tPA and uPA play a role in the pathogenesis of AD.However,these studies have focused on the ability of these plasminogen activators to trigger plasmin-induced cleavage of insoluble Aβ-containing extracellular plaques.In contrast,recent evidence indicates that activity-dependent release of uPA from the presynaptic terminal of cerebral cortical neurons protects the synapse from the deleterious effects of soluble Aβvia a mechanism that does not require plasmin generation or the cleavage of Aβfibrils.Below we discuss the role of the PA system in the pathogenesis of AD and the translational relevance of data published to this date. 展开更多
关键词 Alzheimer’s disease amyloid precursor protein amyloidβ NEUROSERPIN PLASMIN plasminogen activating system plasminogen activator inhibitor-1 synapse tissue-type plasminogen activator urokinase-type plasminogen activator
下载PDF
Protein Microarrays for Quantitative Detection of PAI-1 in Serum 被引量:1
13
作者 Xu Ma Qing-yun Zhang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2012年第3期220-225,共6页
Objective: Plasminogen activator inhibitor-1 (PAI-1), one crucial component of the plasminogen activator system, is a major player in the pathogenesis of many vascular diseases as well as in cancer. High levels of ... Objective: Plasminogen activator inhibitor-1 (PAI-1), one crucial component of the plasminogen activator system, is a major player in the pathogenesis of many vascular diseases as well as in cancer. High levels of PAI-1 in breast cancer tissue are associated with poor prognosis. The aim of this study is to evaluate rigorously the potential of serum PAI-1 concentration functioning as a general screening test in diagnostic or prognostic assays. Methods: A protein-microarray-based sandwich fluorescence immunoassay (FIA) was developed to detect PAI-1 in serum. Several conditions of this microarray-based FIA were optimized to establish an efficacious method. Serum specimens of 84 healthy women and 285 women with breast cancer were analyzed using the optimized FIA microarray. Results: The median serum PAI-1 level of breast cancer patients was higher than that of healthy women (109.7 ng/ml vs. 63.4 ng/ml). Analysis of covariance revealed that PAI-1 levels of the two groups were significantly different (P0.001) when controlling for an age effect on PAI-1 levels. However, PAI-1 values in TNM stage I?IV patients respectively were not significantly different from each other. Conclusion: This microarray-based sandwich FIA holds potential for quantitative analysis of tumor markers such as PAI-1. 展开更多
关键词 Breast cancer plasminogen activator inhibitor-1 Protein microarray SERUM
下载PDF
RFLPs FOR HUMAN PAI-1 GENE IN CHINESE
14
作者 徐也鲁 吴瑜 +5 位作者 龚国胜 余世勤 王伟成 胡燕琴 陈赛娟 陈竺 《Medical Bulletin of Shanghai Jiaotong University》 CAS 1992年第2期35-39,共5页
Plasminogen activator inhibitor 1 (PAI-1) is considered as the main physiological inhibitor of plasminogen activators in plasma which plays an important regulatory role in the control of the fibrinolytic activity in b... Plasminogen activator inhibitor 1 (PAI-1) is considered as the main physiological inhibitor of plasminogen activators in plasma which plays an important regulatory role in the control of the fibrinolytic activity in blood. The human PAI-1 gene is located at q21-22 region of chromosome 7. By using human PAI-1 cDNA (a gift from Dr. D. Ginsburg) as a probe, restriction fragment length polymorphisms (RFLPs) were studied with 8 different endonucleases in 35 unrelated Chinese individuals and the results showed as follows: (1) Taq Ⅰdetected allelic 2.7 kb and 1.8 kb fragments, with the frequencies of 0.96 and 0.04 respectively, 2.7 kb homozygote and 2.7 kb/1.8 kb heterozygote appeared with frequencies of 91% and 9%. (2) Sac Ⅰidentified an invariant 4.8kb band and a two-allele polymorphism with fragments of either 23 kb or 16 kb whose frequencies were 0.96 and 0.04. 23kb homozygote and 23kb/16kb heterozygote appeared with the frequencies of 91% and 9%. (3) HindⅢrevealed a single two-allele polymorphism with bands at either 25 kb or 14 kb, with the frequencies of 0.34 and 0.66, 25 kb homozygote, 25 kb/14 kb heterozygote and 14 kb homozygote appeared with the frequencies of 23%, 46% and 31% respectively. The restriction fragment with a size of 1.6kb for TaqⅠwas first reported in the present paper. No polymorphism was observed for EcoRI, BamHI, BglⅡ, PvuⅡand Pst Ⅰ. The RFLPs for PAI-1 gene may be served as important genetic markers for study of thrombotic and other PAI-1 related disorders. 展开更多
关键词 plasminogen ACTIVATOR inhibitor-1 (PAI-1) RESTRICTION fragment length POLYMORPHISMS (RFLPs)
下载PDF
Role of connective growth factor in plasminogen activator inhibitor-1 and fibronectin expression induced by transforming growth factor β1 in renal tubular cells 被引量:20
15
作者 张春 孟宪芳 +2 位作者 朱忠华 杨晓 邓安国 《Chinese Medical Journal》 SCIE CAS CSCD 2004年第7期990-996,共7页
Background Connective tissue growth factor (CTGF) contributes greatly to renal tubulointerstitial fibrosis, which is the final event leading to end-stage renal failure. This study was designed to investigate the effe... Background Connective tissue growth factor (CTGF) contributes greatly to renal tubulointerstitial fibrosis, which is the final event leading to end-stage renal failure. This study was designed to investigate the effects of CTGF antisense oligodeoxynucleotides (ODNs) on the expressions of plasminogen activator inhibitor-1 (PAI-1) and fibronectin in renal tubular cells induced by transforming growth factor β1 (TGF-β1) in addition to the role of CTGF in the accumulation and degradation of renal extracellular matrix (ECM).Methods A human proximal tubular epithelial cell line (HKC) was cultured in vitro. Cationic lipid-mediated CTGF antisense ODNs were transfected into HKC cells. After HKC cells were stimulated with TGF-β1 (5 μg/L), the mRNA levels of PAI-1 and fibronectin were measured by RT-PCR. Intracellular PAI-1 protein synthesis was assessed by flow cytometry. The secreted PAI-1 and fibronectin in the medium were determined by Western blot and ELISA, respectively.Results TGF-β1 was found to induce tubular CTGF, PAI-1, and fibronectin mRNA expression. PAI-1 and fibronectin mRNA expression induced by TGF-β1 was significantly inhibited by CTGF antisense ODNs. CTGF antisense ODNs also inhibited intracellular PAI-1 protein synthesis and lowered the levels of PAI-1 and fibronectin protein secreted into the medium.Conclusions CTGF may play a crucial role in the accumulation and degradation of excessive ECM during tubulointerstitial fibrosis, and transfecting CTGF antisense ODNs may be an effective way to prevent renal fibrosis. 展开更多
关键词 connective tissue growth factor antisense oligodeoxynucleotide plasminogen activator inhibitor-1 FIBRONECTIN renal tubular epithelial cells
原文传递
Effects of simvastatin on cigarette smoke extract induced tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in human umbilical vein endothelial cells 被引量:10
16
作者 HU Xiao-yun MA Yu-hui +1 位作者 WANG Chen YANG Yuan-hua 《Chinese Medical Journal》 SCIE CAS CSCD 2009年第19期2380-2385,共6页
Background Cigarette smoking has an influence on both arterial-type and venous-type thrombosis. However, little is known about the direct effect of cigarette smoke extract (CSE) on fibrinolytic activity of human umb... Background Cigarette smoking has an influence on both arterial-type and venous-type thrombosis. However, little is known about the direct effect of cigarette smoke extract (CSE) on fibrinolytic activity of human umbilical vein endothelial cells (HUVECs). Most recently, simvastatin has been marked in its effect on endothelial cells protection and anticoagulation. In this study, the effect of CSE on the expression of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-l(PAl-1) in HUVECs was addressed. The role of simvastatin in CSE-induced fibrinolytic activity changes was investigated as well. Methods The fourth to fifth generation of HUVECs were incubated respectively with 0, 5%, 10% and 20% CSE for 6 hours or exposed to 5% CSE for 0, 4, 6, 8, 12, 24 hours to determine the expression changes of t-PA and PAl-1 protein. Meanwhile, cells were also accordingly exposed either to 5% CSE alone or simvastatin pre-treated and 5% CSE for 24 hours to assess the role of simvastatin in CSE-induced t-PA and PAl-1 protein and mRNA expression in HUVECs. RT-PCR and ELISA techniques were used for detecting the t-PA or PAl-1 mRNA and protein. Results After 6-hour exposure to CSE, the expression levels of t-PA protein in 10% and 20% CSE-treated groups reduced significantly ((0.0365±0.0083) ng/ml, (0.0255±0.0087) ng/ml) when compared with that of control group ((0.0660±0.0120) ng/ml) (P 〈0.05). In contrast, the levels of PAl-1 protein in 5%, 10% and 20% CSE-treated groups increased remarkably ((13.3225±0.5680) ng/ml, (14.2675±1.5380) ng/ml, (14.4292±1.6230) ng/ml) when compared with that of control group ((8.5193_±0.7537)ng/ml) (P〈0.05). After stimulation with 5% CSE for 0, 4, 6, 8, 12, 24 hours, the levels of PAl-1 protein increased over time and reached the peak at 24 hours ((14.6400±1.0651) ng/ml), which was significantly higher than that of control group ((12.0656±0.6148) ng/ml) (P 〈0.05). Additionally, CSE could up-regulate PAl-1 expression at both the mRNA and the protein levels. The levels of PAl-1 mRNA and protein increased significantly in 5% CSE-treated group ((8.8030±0.4745) ng/ml, (1.8155±0.0412) ng/ml) compared with those of control groups ((5.0588±0.2315) ng/ml, (1.3030±0.0647) ng/ml) (P 〈0.01), and decreased after 2-hour simvastatin pre-treatment ((5.4875±0.3166) ng/ml, (1.3975-±0.0297) ng/ml) (P 〈0.01). No significant difference was found at the levels of t-PA protein and mRNA (P 〉0.05). Conclusions CSE inhibits the fibrinolytic activity of HUVECs in vitro. Simvastatin plays a protective role in CSE-induced fibrinolytic malfunction. 展开更多
关键词 cigarette smoke extract SIMVASTATIN tissue-type plasminogen activator plasminogen activator inhibitor-1 human umbilical vascular endothelial cells
原文传递
Rhein inhibits transforming growth factor β1 induced plasminogen activator inhibitor-1 in endothelial cells 被引量:3
17
作者 朱加明 刘志红 +2 位作者 黄海东 陈朝红 黎磊石 《Chinese Medical Journal》 SCIE CAS CSCD 2003年第3期35-40,共6页
Objectives To investigate the effect of rhein on endothelial plasminogen activator inhibitor-1 (PAI-1) mRNA expression and protein production induced by transforming growth factor β1 (TGFβ1), and to explore the mech... Objectives To investigate the effect of rhein on endothelial plasminogen activator inhibitor-1 (PAI-1) mRNA expression and protein production induced by transforming growth factor β1 (TGFβ1), and to explore the mechanism of the protective action of rhein on endothelial cells. Methods A human umbilical endothelium derived cell line (ECV-304) from ATCC was used in this study. The PAI-1 mRNA expression and protein synthesis in the endothelial cells were detected by Northern blot and flow cytometry analysis, respectively. The activity of phospho-p44/p42 MAP kinase induced by TGFβ1 was determined by immunoprecipitation analysis and western blot. Results TGFβ1 rapidly increased PAI-1 mRNA expression in the endothelial cells, and this effect lasted at least 24 hours. The upregulation of PAI-1 mRNA expression induced by TGFβ1 in endothelial cells was inhibited by rhein in a dose-dependent manner. In addition, rhein inhibited endothelial PAI-1 protein production. Further study revealed that rhein had a significant inhibitory effect on the activity of phospho-p44/p42 MAP kinase induced by TGFβ1 in human endothelial cells. Conclusions Our results showed that rhein may have a protective effect on the endothelial dysfunction by inhibiting overexpression of PAI-1, indicating a way for the treatment of vascular diseases. 展开更多
关键词 RHEIN endothelial cells plasminogen activator inhibitor-1
原文传递
Pioglitazone suppresses advanced glycation end product-induced expression of plasminogen activator inhibitor-1 in vascular smooth muscle cells 被引量:2
18
作者 Xiaochen Yuan Naifeng Liu 《Journal of Genetics and Genomics》 SCIE CAS CSCD 2011年第5期193-200,共8页
glycation end products (AGEs) play an important role in vascular complications of diabetes, including fibrinolytic abnormalities. Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARy) agonist, h... glycation end products (AGEs) play an important role in vascular complications of diabetes, including fibrinolytic abnormalities. Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARy) agonist, has recently been shown to reduce circulating plasminogen activator inhibitor-1 (PAI-1 ) levels in diabetes mellitus. In the present study, we investigated the effects of pioglitazone on the expression of local PAI-1 in rat vascular smooth muscle cells (VSMCs) induced by AGEs and the underlying mechanism. The result showed that AGEs could enhance the PAI-1 expression by 5.1-fold in mRNA and 2.7-fold in protein level, as evaluated by real-time RT-PCR and Western blotting, respectively. Pioglitazone was found to down-regulate the AGE-stimulated PAI-1 expression in VSMCs. However, these inhibitory effects were partially attenuated by the PPARy antagonist, GW9662. Furthermore, we found that AGEs induced a rapid increase in phosphorylation and activation of extracellular signal-regulated protein kinase 1/2 (ERK1/2). The ERK kinase inhibitor, U0126, partially prevented the induction of PAI-1 by AGEs. Moreover, pioglitazone was also found to inhibit the pbosphorylation of ERKI/2. Taken together, it was concluded that pioglitazone could inhibit AGE-induced PAI-1 expression, which was mediated by the ERK1/2 and PPARy pathways. Our findings suggested pioglitazone had a therapeutic potential in improving fibrinolytic activity, and consequently preventing thromboembolic complications of diabetes and cardiovascular disease. 展开更多
关键词 AGES PPARΓ PIOGLITAZONE plasminogen activator inhibitor-1
原文传递
Role of major adipokines in hypertension:A literature review
19
作者 Saira Rafaqat Sobia Nasreen Sana Rafaqat 《World Journal of Hypertension》 2023年第1期1-11,共11页
The incidence and prevalence of hypertension are increasing as a consequence of the obesity epidemic.Adipocytes and their variety of factors make contributions to the long-term regulation of blood pressure.The pathoph... The incidence and prevalence of hypertension are increasing as a consequence of the obesity epidemic.Adipocytes and their variety of factors make contributions to the long-term regulation of blood pressure.The pathophysiologic states of hypertension,including obesity,are regulated by the production of adipocytederived factors.Increased body mass index was closely linked to elevated blood pressure.Mostly the hypertensive subjects were obese as well as overweight.There are numerous adipokines,however,this review article only focuses on the major adipokines including chemerin,visfatin,retinol-binding protein 4,plasminogen activator inhibitor-1,monocyte chemotactic protein-1,omentin-1,lipocalin-2,vaspin,progranulin,complement c1q tumor necrosis factor-related protein,and nesfatin-1 role in the pathogenesis of hypertension.This review article concludes the significant association of major adipokines in the pathogenesis of hypertensives.New research should be focused on other newly reported adipokine roles in hypertensive subjects and the management of these adipokines in hypertensive subjects.The discovery of this information could result in the creation of antihypertensive medications,particularly those that focus on obesity-related hypertension. 展开更多
关键词 Chemerin VISFATIN Retinol-Binding Protein 4 plasminogen Activator inhibitor-1 Monocyte Chemotactic Protein-1 OMENTIN-1 Lipocalin-2 VASPIN Progranulin NESFATIN-1
下载PDF
补阳还五汤有效组分对血管内皮细胞抗血栓功能及蛋白激酶C的影响 被引量:15
20
作者 欧明娥 唐利文 邓常清 《中草药》 CAS CSCD 北大核心 2008年第10期1514-1520,共7页
目的探讨补阳还五汤及其有效组分生物碱、苷对凝血酶诱导的血管内皮细胞抗血栓功能改变及蛋白激酶C(PKC)活化的影响。方法以凝血酶(10 U/mL)作用于培养的人脐静脉内皮细胞(ECV304),同时加入药物,24 h后测定上清液中组织型纤溶酶原激活物... 目的探讨补阳还五汤及其有效组分生物碱、苷对凝血酶诱导的血管内皮细胞抗血栓功能改变及蛋白激酶C(PKC)活化的影响。方法以凝血酶(10 U/mL)作用于培养的人脐静脉内皮细胞(ECV304),同时加入药物,24 h后测定上清液中组织型纤溶酶原激活物(tPA)和纤溶酶原激活物抑制物-1(PAI-1)水平、细胞组织因子(TF)、组织因子途径抑制物(TFPI)、凝血酶调节蛋白(TM)mRNA表达及PKCα蛋白表达。结果凝血酶作用内皮细胞后,tPA释放增加(P<0.01),TF、TFPI mRNA表达增强(P<0.05),而PAI-1释放及TM mRNA表达无显著性变化(P>0.05);PKCα表达增强(P<0.05)。补阳还五汤可抑制凝血酶诱导的tPA释放增加(P<0.01),生物碱对tPA释放增加无显著影响(P>0.05);苷(1.25 mg/mL)可使凝血酶诱导的tPA分泌增加(P<0.05);原方、生物碱(2 mg/mL)和苷(5 mg/mL)均可抑制内皮细胞分泌PAI-1(P<0.01)。原方、生物碱(1,2 mg/mL)和苷均可抑制凝血酶诱导的TF mRNA表达增强;生物碱(0.5和1 mg/mL)可抑制TFPI mRNA表达(P<0.05);各药对TM mRNA表达无显著影响;原方、生物碱和苷均可抑制凝血酶诱导的内皮细胞PKCα表达的增强(P<0.01)。PKC激活剂佛波酯(PMA)刺激内皮细胞后,PKCα被激活(P<0.01);PKC抑制剂H7作用于PMA刺激的内皮细胞后,PKCα表达增强不明显,PAR-1受体抑制剂CATG作用于凝血酶刺激的ECV304细胞后,PKCα表达显著抑制(P<0.05)。结论凝血酶可诱导内皮细胞抗血栓性发生变化。补阳还五汤原方、生物碱和苷对凝血酶诱导的血管内皮细胞抗凝、纤溶功能的改变具有调节作用,使血管内皮细胞的抗凝、纤溶作用趋于正常,其作用可能主要是通过抑制凝血酶诱导的PKCα的激活而介导的。生物碱和苷类有效组分可能为该方抗血栓作用的药效物质基础。 展开更多
关键词 补阳还五汤 血管内皮细胞 组织型纤溶酶原激活物 纤溶酶原激活物抑制物-1 蛋白激酶C
下载PDF
上一页 1 2 下一页 到第
使用帮助 返回顶部